Key result
Cyclical bortezomib is linked to acute severe LV systolic dysfunction with EF 20-25%.
Why the study?
Acute cardiac dysfunction is an infrequent but reported side effect of bortezomib in plasma cell neoplasms, requiring further clinical characterization.
Case Report (n=1)
No
Bortezomib therapy can be associated with severe, potentially reversible acute left ventricular systolic dysfunction, highlighting the need for cardiac monitoring.
Bortezomib may induce severe reversible LV systolic dysfunction; this case report leaves open the role of routine cardiac monitoring in plasma cell leukemia.
Bortezomib is an important proteasome inhibitor widely used in plasma cell neoplasms.An acute cardiac dysfunction is not a frequent side effect of bortezomib, but it is mentioned in literature search via multiple case reports.We have discussed here, another case of a young male diagnosed with plasma cell leukemia on treatment, presenting with sudden onset dyspnea due to an acute myocardial toxicity which subsequently upon thorough evaluation turned out to be an association with cyclical bortezomib administration.
No takes yet. Share an insight, caveat, or question.
Rafiq et al. (2016) conducted a case report in Plasma cell leukemia (n=1). Bortezomib was evaluated on Development of acute cardiac dysfunction. A 44-year-old male with plasma cell leukemia developed severe left ventricular systolic dysfunction with an ejection fraction of 20-25% following cyclical bortezomib administration.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: